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2. Abstract 
Introduction:  Renal stones are one of the most painful medical conditions patients experience. 
For many they are also a recurrent problem.  Fortunately, there are a number of drug therapies 
available to treat symptoms as well as prevent future stone formation.  
Areas covered:  Herein, we review the most common drugs used in the treatment of renal 
stones, explaining the mechanism of action and potential side effects.  Search of the Medline 
databases and relevant textbooks was conducted to obtain the relevant information.  Further 
details were sourced from drug prescribing manuals.  Recent studies of drug effectiveness are 
included as appropriate.  
Expert opinion:  Recent controversies include medical expulsive therapy trials and complex role 
of urinary citrate in stone disease. Future directions in research will involve new medical 
therapies for stone prevention, for example new drugs for hyperoxaluria. 
3. Keywords 
Adrenergic alpha-antagonists, analgesics, anti-inflammatory agents non-steroidal, bicarbonates, 
drug therapy, kidney calculi, renal colic, thiazides 
4. 1 Introduction 
Renal stones are a common cause of morbidity around the world. The incidence of kidney stones 
is increasing globally1. These increases are seen across sex, race, and age and are multifactorial.  
In the USA, 20- to 74-year-old adults have at least a 5%-8% chance of being diagnosed with 
kidney stones during their lifetime2, 3. There are a number of drugs used in stone treatment, 
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prevention, and relief of associated symptoms. In this article we review the most common drugs 
prescribed for treatment and prevention of renal calculi as well as their potential adverse effects. 
4.2 Body  
The pharmacological management of renal calculi can be broadly divided into two categories: 
those that treat symptoms and those that treat progression of the stone disease as such. The 
choice of medications is dependent upon patient factors, stone analysis results and serum/urine 
biochemistry studies. Detailed patient work up is required before commencing any drug therapy. 
4.2.1 Drugs used to treat existing or prevent future stones  
The specific drug prescribed is dependent on the type of renal stone a particular patient forms as 
in many instances unique treatments are tailored to unique types of stones.  This requires 
thorough patient evaluation and confirmatory laboratory studies. As an example, uric acid calculi 
can occasionally be dissolved with urinary alkalinisation by raising urinary pH to the 6.5 range4. 
This treatment however might actually worsen stone formation in a patient who forms calcium 
phosphate stones.  Furthermore, certain biochemical abnormalities (e.g. hypercalciuria) are 
known to predispose to stone formation5 and can be corrected with medications.  
4.2.1.1 Thiazides 
Thiazide diuretics are commonly used to reduce the risk of calcium stone recurrence. Common 
drugs and doses are listed in Table 15.  Thiazides exert their effect by reducing urinary calcium 
excretion, thereby reducing hypercalciuria. Thiazides can be effective in both normocalciuric and 
hypercalciuric patients. The beneficial effects have been confirmed in several studies6,7 over the 
last 55 years and are summarized in the recent AUA guideline on medical management of kidney 
stones5.  Thiazides directly stimulate calcium resorption in the distal nephron while reducing the 
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extracellular fluid compartment. The hypocalciuric effect only takes 2-3 days to be established 
and is limited to thiazide types of diuretics only.  It does not extend to other diuretic classes such 
as loop or potassium-sparing diuretics8.  Significantly, thiazides can induce hypocitriuria due to 
hypokalemia and resultant intracellular acidosis. Potassium supplementation (in potassium 
chloride or potassium citrate form) will correct the hypocitriuria. Since citrate is a renal stone 
inhibitor, low citrate levels can contribute to stone formation9. 
Table 1. Common diuretic doses for calcium stone prevention5 
Drug name Dose 
Hydrochlorothiazide (HCTZ) 25mg orally, twice daily  
OR 
50mg once daily 
Chlorthalidone 25mg orally, once daily 
Indapamide (non-thiazide diuretic) 2.5mg orally, once daily 
Chlorothiazide10 0.5-1g orally, once daily  
*Liquid formulation* 
Amiloride / HCTZ11 5mg / 50mg tablet, once daily 
Triamterene / HCTZ12 37.5mg / 25mg, once daily 
 
While generally well tolerated at low doses, the potential for side effects with thiazides is 
present. In some studies the side effects are significant enough to stop treatment in 1:6 patients.  
In the majority of cases; however, they do improve with time13,8. The most common side effects 
are dizziness (due to postural hypotension), weakness and fatigue.  Other potential side effects 
include thirst, polyuria, muscle cramps, reversible erectile dysfunction, nausea, vomiting, gastric 
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irritation, diarrhea or constipation, rashes, skin reactions, purpura and blood dyscrasias including 
thrombocytopenia. Uncommonly, precipitation of gout or diabetes can occur; very rarely 
pancreatitis and hepatic encephalopathy have been reported14.  Gout and diabetes precipitation is 
likely due to disturbances of serum uric acid and glucose levels that have been described with 
thiazide administration14. It is essential to obtain serum potassium measurement when starting 
thiazide treatment as hypokalemia can occur (due to indirect stimulation of potassium 
excretion15).  This is particularly true in the context of dehydration e.g. vomiting and diarrhea. 
Serial serum potassium levels should be checked at regular intervals. It is recommended that 
concomitant potassium supplementation be administered whenever a thiazide is commenced.  
Thiazide use requires caution in renal or liver failure and elderly patients. Mild hypercalcemia is 
not uncommon. Occasionally administration of a thiazide can unmask primary 
hyperparathyroidism8.  Finally, there are several important drug interactions detailed in table 2. 
Table 2. Diuretics in renal stone disease – important drug interactions16 
Drug Hydrochlorothiazide Chlorthalidone Indapamide 
Cardiovascular 
effects 
Alcohol, barbiturates 
or narcotics 
exacerbate orthostatic 
hypotension 
Alcohol, barbiturates 
or narcotics 
exacerbate orthostatic 
hypotension 
 
Altered drug effects Diabetic drugs – may 
require dose 
adjustment. 
NSAIDS  – reduce 
Potentiate action of 
other 
antihypertensives. 
Diabetic drugs – may 
May potentiate other 
antihypertensives. 
Diabetic drugs – may 
require dose 
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diuretic/ natriuretic 
function 
require dose 
adjustment 
adjustment 
 
Impaired drug 
absorption 
Anionic exchange 
resins  
(e.g. cholestyramine, 
colestipol) reduce 
thiazide absorption 
  
Metabolic effects Corticosteroids and 
ACTH hormone may 
intensify electrolyte 
depletion 
Corticosteroids and 
ACTH hormone may 
intensify electrolyte 
depletion. 
Digitalis may worsen 
hypokalemia effects, 
derange electrolytes 
Corticosteroids, and 
ACTH hormone may 
intensify electrolyte 
depletion. 
Digitalis may worsen 
hypokalemia effects, 
derange electrolytes 
Toxicity Increased lithium 
toxicity risk 
Increased lithium 
toxicity risk 
Increased lithium 
toxicity risk 
Contraindications Sulfonamide-derived 
drug hypersensitivity 
(relative)  
Sulfonamide-derived 
drug hypersensitivity 
(relative)  
Sulfonamide-derived 
drug hypersensitivity 
(relative)  
 
Indapamide is an indoline-class diuretic, similar to thiazides in its effect on urinary calcium 
excretion17 . It is utilized in calcium stone prevention with fewer side effects than thiazide 
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diuretics18. Cases of severe hyponatremia have been reported. Indapamide should not be used in 
severe renal or hepatic disease19. 
Amiloride is a diuretic commonly administered together with thiazide. Amiloride does not affect 
potassium excretion, reducing the risk of hypokalemia. In fact, in certain high risk patients, e.g. 
renal failure it can cause hyperkalemia, necessitating a boxed FDA warning. Caution will be 
required if other potassium containing medications are used or in patients with renal 
impairment20. Amiloride can cause hypocalciuria, thereby potentiating this effect of thiazide 
diuretics when given in combination21. 
4.2.1.2 Urinary alkalinizers 
Urinary alkalinizers such as potassium citrate can be used in patients with hypocitriuria. 
Increased urinary citrate increases the pH of urine and can act as an inhibitor of calcium oxalate 
and calcium phosphate stone formation22,23. Urinary inhibitors, such as citrate, prevent crystal 
growth and aggregation by coating the surface of the growing calcium crystals without changing 
the concentration of calcium oxalate or phosphate. In the case of citrate, stone inhibition is 
achieved by it forming a complex with urine calcium, thereby directly decreasing the saturation 
of calcium oxalate and calcium phosphate24. Citrate is also an inhibitor of crystallization25. 
Important causes of low urinary citrate excretion associated with renal stone disease include use 
of thiazides, renal tubular acidosis, urinary tract infection, hypokalemia associated with 
potassium depletion, magnesium depletion, bowel disease and idiopathic causes. Interestingly, 
irrespective of dietary intake, most of the circulating citrate is derived endogenously from 
oxidative metabolism26. Randomized trials have confirmed that potassium citrate administration 
reduces the risk of recurrent calcium stones5. Furthermore, alkalinizers can be utilized in 
thiazide-induced hypocitriuria and in uric acid calculi dissolution and prevention therapy. They 
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are also a useful adjunct in patients with renal tubular acidosis type 1 and cystinuria. One must 
be cautious not to over alkalinize the urine as doing so can lead to a net increase in the risk of 
calcium phosphate stone formation whose growth is favored by an alkaline urinary pH5.   
There is a range of doses and formulations available, from tablets (UROCIT®-K Mission 
Pharmacal Company) and liquids to effervescent drinks27. Several formulations are detailed in 
Table 3. A more extensive list is available in the Appendix. 
Table 3. Common urinary alkalinizers 
Drug UroCit-K28 Polycitra-K29 Oracit30 Bicitra31 
Active 
ingredients 
Potassium citrate Potassium citrate Sodium citrate Sodium citrate 
Formulation Extended release 
tablets 
Crystals or liquid Liquid Liquid 
Dose 1/2mEq/kg/day 
in divided doses 
30 to 60 
mEq/day 
10 to 30 mL 
diluted, after 
meals 
10 to 30 mL 
diluted, after 
meals 
 
The two primary alkalinizer categories are potassium citrate compounds and sodium citrate 
compounds. Sodium citrate is not recommended as increased sodium load will increase urinary 
calcium levels32. The most common side effect is gastrointestinal upset, improved by taking the 
drug with water and soon after a meal33. The most dangerous effect of potassium containing 
supplements is hyperkalemia, particularly dangerous in patients with renal failure23. This can be 
life-threatening, especially in combination with potassium-sparing diuretic therapy. Careful 
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serum electrolyte monitoring is required. In such cases, sodium containing supplements may be 
preferred as they avoid the hyperkalemia risk.  However, these are suboptimal for stone formers 
as the increased sodium load can increase urinary calcium excretion, with increased risk of 
calcium stones32, thereby offsetting the beneficial effects of urinary alkalinization. High doses of 
sodium containing supplements can cause fluid overload in patients with pre-existing renal 
dysfunction or cardiac failure. Other precautions for urinary alkalinizers include presence of 
struvite stones and upper GI tract disease such as ulcers, gastritis and delayed gastric emptying34. 
A starting dose of UROCIT®-K Mission Pharmacal Company is 1/2mEq/kg/day in divided 
doses. Typically, the dose of alkalinizer is titrated until desired urinary pH (e.g. 6-6.5) is 
achieved. Raising urinary pH to > 7 can increase risk of calcium phosphate stones and should be 
avoided5. This is due to an increase in the saturation of calcium phosphate at high pH. Increased 
urine pH shifts the equilibrium between HP042- and H2PO4- in favor of the former, thereby 
tending to precipitate out the less soluble brushite (CaHPO4·2H20).  
Calcium citrate can be used to bind oxalate in the gut in enteric hyperoxaluria35. It will also 
increase urinary citrate excretion thereby offsetting increased urinary calcium excretion36. A 
recommended dose is 200–400 mg and must be taken with meals to maximize oxalate binding 
effect and minimize calcium absorption37.  
4.2.1.3 Xanthine oxidase inhibitors 
These drugs are commonly used in patients with hyperuricosuria and either uric acid or calcium 
stones. Uric acid stones account for approximately 9% of renal calculi in the USA38. 
Furthermore, monosodium urate or uric acid crystals can act as seed crystals for calcium oxalate 
or adsorb normally occurring inhibitors of calcium oxalate crystallization39. It is important to 
note that the majority of patients with uric acid calculi have low urinary pH and normal urinary 
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uric acid levels40,41. Allopurinol is a xanthine oxidase inhibitor that reduces both serum and 
urinary uric acid levels. It was first noted as part of the drug discovery program at Burroughs 
Wellcome that started in 1940s and culminated in a 1988 Nobel Prize in Physiology and 
Medicine. Although generally well tolerated, the most common adverse effects of allopurinol are 
gastrointestinal distress, hypersensitivity reactions, hepatotoxicity and skin rash42,43. Minor 
hypersensitivity reactions to allopurinol, including pruritus and dermatitis, occur in 
approximately 2% of patients44. More serious adverse events associated with allopurinol include 
fever, toxic epidermal necrolysis, alopecia, bone marrow suppression, hepatitis, and vasculitis43. 
Severe allopurinol-induced toxic effects are rare but can be life-threatening. A dose dependent 
allopurinol hypersensitivity syndrome is associated with a mortality rate of approximately 20%45. 
Several drug interactions can also occur. Increased toxicity with thiazide diuretics has been noted 
(patients who are already taking thiazides for hypercalciuria are at a particular risk) and renal and 
hepatic function monitoring is required46.  
Febuxostat is a new type of xanthine oxidase inhibitor. It is preferred in renal impairment as it is 
hepatically cleared47.  A recent 2013 trial showed that febuxostat significantly lowered 24-hour 
urinary acid excretion in patients with calcium stones, compared to allopurinol. There was no 
change in stone size or number, although the study was only six months in duration48. Adverse 
reactions occurring in at least 1% of Febuxostat-treated patients, and at least 0.5% greater than 
placebo, are: liver function abnormalities, nausea, arthralgia, and rash49. Trials of febuxostat for 
uric acid and calcium calculi prevention are still awaited. 
4.2.1.4 Treatments for cystinuria 
Cystinuria is an inherited autosomal recessive condition, due to a defect in intestinal and renal 
tubular transport of dibasic amino acids, including cystine50. As a result of high urinary cystine 
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levels and poor solubility of cystine these patients form multiple stones, often from an early age. 
Initial therapy involves hydration to reduce cystine concentration and reduced oral intake of 
sodium and protein. Urinary alkalinization is the next step, aiming for pH >751 since higher 
urinary pH increases solubility of cystine52.  Potassium citrate, as discussed above, is frequently 
utilized. If these simple measures are inadequate, additional medications are used. 
4.2.1.4.1 Tiopronin (Thiola ® Mission Pharmacal Company) 
Tiopronin is the active reducing agent that undergoes thiol-disulfide exchange with cystine to 
form a mixed disulfide of Thiola-cysteine53. This mixed disulfide is far more soluble than 
cystine, thereby reducing pure cystine excretion and stone formation. The drug is only available 
in a 100mg tablet form. Exact dose is dependent on the desired reduction in the urinary cystine 
excretion. Urinary cystine concentrations are monitored with 24-hour urine testing, so that dose 
adjustments can be made. Typically, the urinary cystine concentration target is < 300mg/L 
(cystine solubility limit) to be maximally effective54. An average dose in the study of cystinuria 
patients was approximately 1100mg/day.  Tiopronin has fewer side effects than d-penicillamine, 
a drug also used in cystinuria treatment. Nevertheless, both drugs have significant side effects 
with 30% of patients needing to stop treatment in one study55. Tiopronin side effects include 
drug fever, rash and pruritus (1 in 6 patients), as well as SLE-type reaction and skin changes with 
longer term use. Gastrointestinal side-effects occur in 1 in 6 patients, including nausea, vomiting, 
diarrhea and abdominal pain. Significantly, there is a 1 in 25 risk of hematological abnormalities 
including bleeding, anemia, leukopenia, thrombocytopenia and eosinophilia53. Other less 
common effects include hypersensitivity reactions, renal complications including proteinuria and 
nephrotic syndrome (1 in 20 patients) and pulmonary manifestations including bronchiolitis, 
hemoptysis and dyspnea in 1 in 50 patients. Unfortunately, severe reactions are more likely to 
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occur in patients who already developed adverse effects with another cystinuria drug, d-
penicillamine. Given these significant side effects, close monitoring including frequent 
hematological, renal and liver function testing is essential.  
4.2.1.4.2 D-penicillamine 
D-penicillamine acts similar to tiopronin by forming penicillamine-cysteine disulfide that has 
higher solubility than cystine. Since the side effects are more significant, it is usually reserved as 
a second-line option. Significant hematological side effects including leukopenia, 
thrombocytopenia, pancytopenia, aplastic anemia and agranulocytosis have been reported, even 
leading to fatalities56. Proteinuria and hematuria can also develop, progressing to nephrotic 
syndrome. Hemoptysis and pulmonary infiltrates can also occur. Skin rashes and pemphigus 
occur in a small number of patients as does myasthenic syndrome. Myasthenic syndrome is 
characterized by progressive, and typically symmetric, muscle weakness.  With D-penicillamine, 
symptoms usually start 4 to 9 months after initiation of treatment57. The symptoms are generally 
mild and may be limited to extra ocular muscles. Close monitoring of hematological, renal and 
hepatic parameters is mandatory, initially with twice-weekly tests and clinical examination. 
Typical dose starts with 250mg/day and is increased to 500mg qid as required to reduce urinary 
cystine concentration. 
4.2.1.4.3 Captopril 
Captopril is an ACE inhibitor that contains thiol compounds. There are literature reports of its 
use in cystinuria58, 59. However other studies have failed to confirm effectiveness60, 61. As a result 
it is not routinely used in the treatment of cystinuria patients unless there is the presence of 
concomitant hypertension.  
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4.2.1.5 Acetohydroxamic acid (AHA) 
Struvite stones form as a result of urinary tract infection with urease-splitting organisms, 
including Proteus, Pseudomonas and Klebseilla (Table 4).  The hydrolysis of urea by bacterial 
urease enzyme increases urinary pH and ammonia levels, with consequent stone formation62.  
Table 4. Urease-producing microorganisms63 
Organism Usually produces urease  
(>90% of isolates) 
Occasionally produces urease  
(5-30% of isolates) 
Gram positive 
bacteria 
Staphylococcus aureus Staphylococcus epidermidis 
Gram negative 
bacteria 
Proteus mirabilis 
Proteus subspecies (vulgaris, 
rettgeri, morgani) 
Providencia stuartii 
Providencia rettgeri 
Enterobacter gergoviae 
Klebsiella pneumoniae 
Klebsiella oxytoca 
Serratia marcescens 
Pseudomonas aeruginosa 
 
Yeasts Cryptococcus 
Rhodotorula 
Sporobolomyces 
Candida humicola 
Trichosporon cutaneum 
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Classically, these bacteria form staghorn calculi, often requiring invasive surgical treatment. 
Acetohydroxamic acid binds urease, inhibiting its action and reducing the likelihood of struvite 
stone formation64. It does not acidify urine or have a direct antibacterial effect. It is used in 
patients with urease-splitting UTI at a dose of 1g/day in divided doses. AHA is utilized after 
surgical treatment options have been exhausted, given its significant side-effects5 in up to 30% of 
patients65. Common reactions include tremors, headache (mild and transient), gastrointestinal 
symptoms (primarily mild) and alopecia. Regular hematologic testing is required as hemolytic 
anemia occurs in 3-15% of patients necessitating cessation of the medication.  Mild hemolysis 
occurs in most patients as evidenced by elevated reticulocyte counts. If the reticulocyte count 
exceeds 6%, a reduction in dosage should be considered66. Superficial phlebitis and embolic 
phenomena were reported in a small number of patients, resolving with discontinuation of AHA. 
Finally, depression, anxiety and nervousness were significant enough to stop treatment in 6% of 
patients65. AHA should not be administered to patients with renal impairment as it can lead to 
drug accumulation with resultant toxicity. Furthermore, clinical experience with this drug is 
limited with long-term effects unknown. Due to its toxicity and expense, AHA is indicated only 
in patients with recurring struvite stone formation and recalcitrant urealysis who are not suitable 
for surgical stone treatment. 
4.2.2 Drugs used in managing stone symptoms 
Acute renal colic is considered to be one of the most excruciatingly painful medical conditions. 
A range of analgesia options is available to control acute symptoms. As always, full medical 
history, examination and appropriate tests are conducted before drugs are prescribed. In 
particular, renal function can be affected by renal calculi causing obstruction. Significant renal 
impairment will preclude the use of several analgesics. 
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4.2.2.1 Acetaminophen 
Acetaminophen is one of the most commonly prescribed analgesics around the world. It has an 
excellent safety profile. Despite its popularity and use for over 100 years, the mechanism of 
action is still not fully elucidated. It is thought to have a weak cyclooxygenase inhibitor action67. 
Acetaminophen has potent anti-pyretic and analgesic actions, despite very weak anti-
inflammatory activity. It is used as part of the acute management of renal colic. In randomized 
trials intravenous acetaminophen was as effective as intravenous morphine in relieving acute 
renal colic pain68, 69.  As for any drug, there is a small risk of hypersensitivity reaction. High 
doses >4000mg/24 hours or together with high alcohol intake can cause severe liver damage70. 
Caution is required in patients with liver or kidney impairment. Thrombocytopenia and hepatic 
dysfunction (at recommended doses) have been reported very rarely (<1/10,000 patients)71. 
Immediate medical attention is warranted in the event of an overdose due to risk of permanent 
liver injury, and may require administration of N-Acetyl-Cysteine72. 
4.2.2.2 Cyclooxygenase inhibitors 
Cyclooxygenase (COX) enzyme produces prostaglandins. These are mediators of multitude of 
bodily functions, from physiological, such as gastric protection, platelet and renal function, to 
pathological, such as fever, pain and inflammation73. In particular, PGE2 and prostacyclin are the 
main inflammatory mediators. Aspirin, diclofenac, ketorolac and similar non-steroidal anti-
inflammatory drugs (NSAIDs) inhibit cyclooxygenase prostaglandin synthesis and therefore 
have anti-inflammatory, antipyretic and analgesic effects. These are some of the most commonly 
used drugs for management of renal colic. In a 2004 systematic review of 20 trials, 1613 patients 
given NSAIDs for renal colic achieved greater reductions in pain scores, were less likely to 
require rescue analgesia or develop vomiting than patients given opioids74. In a Cochrane review 
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of 5734 patients from 2015, NSAIDs were again shown to be effective in acute renal colic75. 
However, these powerful drugs are not without problems. Due to disruption of protective 
functions of prostaglandins, NSAIDs can cause a range of side effects. An important adverse 
effect of NSAIDs is renal impairment, particularly relevant to patients with renal stones who 
may already have a degree of renal dysfunction, either acutely (due to urinary tract obstruction) 
or chronically. NSAIDS inhibit prostaglandin synthesis therefore reducing renal cortical blood 
flow76. Furthermore, NSAIDS can cause interstitial nephritis with nephritic syndrome and 
(rarely) irreversible renal papillary necrosis77. Hence, renal function monitoring is essential in 
any patients taking these drugs. NSAIDS are contraindicated in patients with significantly 
reduced renal function. 
NSAIDs have increased risk of gastrointestinal inflammation, bleeding, ulceration and even 
perforation78. This warrants careful review, if not outright contra-indication of NSAIDs in 
patients with pre-existing gastric ulcers. Risk factors for NSAID-related GI complications 
include a previous GI event (especially if complicated), age, concomitant use of anticoagulants, 
corticosteroids, other NSAIDs including low-dose aspirin, high-dose NSAID therapy, and 
chronic debilitating disorders, especially cardiovascular disease79. In selected patients, after 
assessing their GI ulceration risk factors, proton pump inhibitors (e.g. omeprazole) can be used 
to reduce risk of gastric and duodenal ulcers and their complications79. Finally, any high-risk 
patients starting long-term NSAID therapy should be tested for and treated for H. Pylori 
infection first80. NSAIDS can also increase cardiovascular thrombotic risks including MI and 
stroke, necessitating a boxed FDA warning in the USA. Hence, patient’s cardiovascular risk 
profile needs to be assessed prior to starting NSAID treatment. Other side effects of COX 
inhibitors include fluid retention, hypertension, anaphylactoid reaction, skin reactions 
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(exfoliative dermatitis, Stevens-Johnson syndrome), worsening of asthma control, anemia, 
prolonged bleeding time and liver dysfunction. Prolonged bleeding time and coagulopathic 
effects are significant in renal stone patients who may require surgery78. While minimally 
invasive ureteroscopy and laser lithotripsy can safely be performed with anticoagulation81, 
procedures such as ESWL and PCNL will require cessation of NSAIDs (with or without bridging 
therapy, as dictated by the thrombotic risk profile).  
4.2.2.3 Ketorolac  
Ketorolac tromethamine is one of the most commonly used NSAID drugs for the treatment of 
renal colic. In addition to inhibiting prostaglandin synthesis, it may act centrally to diminish 
perception of pain and reduce ureteric musculature activity82. It is typically given in IV or IM 
form. Tablets (only as continuation of IV form) are also available. Ketorolac has been shown to 
be more effective than meperidine (narcotic analgesic) in renal colic83. Ketorolac carries a boxed 
FDA warning with total combined duration of oral and injectable use not to exceed 5 days84. 
Ketorolac side effects are representative of NSAID class in general, including GI bleeding and 
ulceration, increased risk of cardiovascular thrombotic events, MI and stroke. It should not be 
used prior to any major surgery, in patients at risk of renal impairment, or in patients >70 years 
of age. Prolonged bleeding time and coagulopathic effects are noted as with the rest of the 
NSAID medications. Common adverse reactions include nausea, dyspepsia, abdominal pain, 
dizziness and drowsiness. 
4.2.2.4 COX-2 inhibitors 
A newer class of drugs, COX-2 inhibitors, acts by suppressing inflammatory mediators produced 
specifically by COX-2 enzyme. COX-1 enzyme has protective physiological functions, such as 
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anti-thrombogenic and cytoprotective effects. COX-2 enzyme is primarily expressed in response 
to inflammation or other pathological event73. Hence, specific COX-2 inhibitors such as 
celecoxib and parecoxib are thought to possess less (although not negligible) gastrointestinal 
toxicity. Unfortunately, as demonstrated in VIGOR study (and ensuing controversy) this comes 
at a price of increased myocardial infarction and stroke rates85. Following the fall-out from the 
VIGOR trial, rofecoxib has been withdrawn from the market. Other COX-2 inhibitors carry 
boxed FDA warning of increased cardiovascular and stroke events86. Patients with pre-existing 
cardiovascular or GI ulcer disease (or risk factors) should avoid COX-2 inhibitors. Other side 
effects of COX-2 inhibitors include onset of or worsening hypertension and fluid retention. 
Hepatic reactions can occur and liver function tests (LFTs) need to be monitored86. Renal 
impairment risk is noted, particularly with long-term use. This has implications for renal calculi 
patients who frequently have either acute or chronic renal impairment. As with other NSAIDs, 
asthmatic patients may develop worsening symptoms. Rarely, serious skin reactions e.g. 
exfoliative dermatitis and Stevens-Johnson syndrome have been reported. While COX-2 
inhibitors have been previously studied in the management of renal colic87, due to increased 
cardiovascular risks their current use is limited, especially in the setting of renal colic. 
4.2.2.5 Opioid analgesics 
Opiods are a large class of analgesics, including diverse drugs such as morphine, hydrocodone, 
oxycodone, fentanyl, codeine and methadone. Opiods are available in oral, intramuscular and 
intravenous formulations. The earliest opioids were derived from the seeds of poppy plants. 
Opioid drugs are typically reserved for more severe pain conditions, when alternative 
medications are ineffective. Opioids mimic the actions of endogenous opioid peptides by 
interacting with mu, delta or kappa opioid receptors in the central nervous system. They also 
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decrease intracellular cAMP which modulates the release of nociceptive neurotransmitters (e.g. 
substance P)88. Opioids have been shown in systematic review to be effective in management of 
renal colic (albeit less effective than NSAIDS)74. Unfortunately, opioids can cause a number of 
unpleasant side effects. Most common effects include gastrointestinal (nausea, vomiting, 
constipation) and central nervous system (drowsiness, hypotension and respiratory depression)89. 
In particular, patients with respiratory or renal impairment (more frequent amongst patients with 
renal colic) are at increased risk of opioid accumulation and resultant respiratory depression. In 
certain patients at risk (e.g. elderly and cachectic, other CNS depressants, renal impairment) 
respiratory depression can be life-threatening. Other opioid side effects include headache, 
peripheral edema, rash, insomnia and depression90. Any patient on opioid medications can 
develop opioid tolerance and potential for abuse/addiction. This is a significant issue, requiring 
boxed FDA warning in USA. Tolerance develops with the repeated use of opioids requiring 
increasing doses to maintain analgesic effects91. Rotation of various opioid drugs can be useful in 
managing tolerance. Meperidine in particular has high risk of developing tolerance92,93. It also 
carries a risk of serotonin syndrome when combined with certain medications, such as 
antidepressants94. Given these concerns, meperidine use in the US has declined significantly, 
although it remains in use worldwide. 
4.2.2.6 Tramadol 
Tramadol is an atypical opioid analgesic. Its mechanism of action is two-fold, mediated by 
opioid (mu) and non-opioid (inhibition of monoamine uptake) pathways95. Many of the side 
effects are similar to the opioid drugs, although potential for tolerance and addiction is lower. 
There is some evidence of its use for renal colic96 but further studies are needed. Common 
adverse effects include dizziness, nausea and vomiting, constipation, headache, drowsiness, 
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sweating, dry mouth, dyspepsia, diarrhea and pruritus97. Tramadol is known to lower seizure 
threshold in patients with epilepsy or head injury. Caution needs to be exercised in patients with 
emotional disturbances, depression and in elderly. Finally, there is risk of serotonin syndrome if 
used concurrently with SSRIs, tricyclic antidepressants or MAOIs98. Serotonin syndrome is a 
rare and potentially life-threatening toxic state due to excessive serotonergic activity. It 
classically presents with altered mental status, abnormal neuromuscular tone and autonomic 
hyperactivity and is typically treated with cessation of offending drug and supportive care99. 
4.2.2.7 Phenazopyridine hydrochloride 
Phenazopyridine hydrochloride (Pyridium® Gemini Laboratories, LLC) is a urinary tract 
analgesic that exerts a topical analgesic effect on urinary tract mucosa. It is particularly useful for 
treatment of dysuria, frequency and urgency associated with stone passage or stone surgery. It is 
also helpful for management of stent symptoms100. A typical dose is 200mg tablets three times 
daily. Common adverse effects include headache, rash, pruritus and GI disturbance. It is 
contraindicated in renal insufficiency101. The drug causes reddish-orange discoloration of urine 
and may stain fabric and contact lenses. It should not be used for more than a few days as it can 
mask important symptoms such as infection. 
4.2.2.8 Alpha-blockers 
Alpha-1-adrenergic receptor antagonists are used in the medical management of ureteric stones 
as part of MET (medical expulsion therapy). MET uses drugs to relieve symptoms in 
uncomplicated renal colic thereby reducing the need for invasive procedures as some stones will 
pass spontaneously.  The alpha-1 adrenergic receptors are predominantly located in the distal 
ureter102. Administration of alpha-1-adrenergic blockers can improve expulsion rates of distal 
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ureteric stones as it allows relaxation of the ureteric muscle103, although this is an off-label use. 
Alpha-1-adrenergic blockers are also used as an aide in shock wave lithotripsy to improve stone-
free rates. Alpha-blockers have also been useful in reducing stent-associated symptoms and 
pain104. Common alpha-1 blockers include terazosin and doxazosin. Usual dosing is outlined in 
Table 5. Significant side effects include postural hypotension and syncope (vasodilatation due to 
the adrenergic blockade effects). Gradual dose titration and administration at night are 
recommended to reduce these unwelcome effects105. Other side effects are asthenia, headache, 
nasal congestion, nausea, peripheral edema and priapism. 
Table 5 – Common alpha-blockers 
Drug Terazosin Doxazosin Tamsulosin Alfuzosin SR 
Mechanism of 
action 
α1 blocker α1 blocker α1a /α1d  receptor 
blocker 
α1 blocker  
slow release 
Typical dose 5mg daily 2-4mg daily 0.2-0.4mg daily 10mg 
 
Tamsulosin is an alpha-adrenergic antagonist with equal affinity for α1a and α1d receptors106. 
Since the α1dreceptor is the predominant subtype in the ureter107, tamsulosin blockade can 
improve ureteric relaxation. Tamsulosin has been shown to improve stone passage rates by up to 
a third in several studies, including by De Sio et al in 2006108. It also reduced both the 
requirement for analgesia and mean stone passage time. However, in 2015 a large randomized 
trial of 1167 patients (SUSPEND trial) assessing the efficacy of alpha blockers (and calcium 
channel blockers) vs. placebo failed to demonstrate a significant benefit in stone passage109. 
Tamsulosin has similar side-effect profile to other alpha-1 blockers but without the need for dose 
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titration, allowing greater convenience for the patients at therapy initiation. Tamsulosin has a 
slightly higher incidence of ejaculatory dysfunction, due to its affinity for dopaminergic and 
other central nervous system receptors110.  
Alfuzosin SR is another α1 selective blocker, with reduced risk of ejaculatory dysfunction111. It 
has also been shown to reduce stent symptoms in a randomized trial112. 
4.2.2.9 Corticosteroids 
Corticosteroid drugs, such as prednisolone and deflazacort have potent anti-inflammatory effects. 
It is thought that these anti-inflammatory effects may improve stone passage by relieving ureteric 
edema resulting from stone impaction113. Several trials had showed faster stone passage with the 
addition of corticosteroid114,115. However, routine use of corticosteroids is limited by the 
significant adverse effects. The potent anti-inflammatory actions suppress immune response to 
intercurrent infections. Corticosteroids can cause salt/water retention, muscle weakness, 
Cushinoid state, impaired glucose tolerance, impaired wound healing and osteoporosis. Hence 
these medications are rarely used in managing renal stone disease. 
4.2.2.10 Rowatinex  
Rowatinex is an essential oil preparation of terpenic type. Terpenes are known to have diuretic 
and antibacterial effects as well as spasmolytic and hyperemic effects. Rowatinex was first 
shown to be effective in a small randomized trial in 1987116.  In a randomized study of 222 
patients in 2011 it was shown to be more effective than placebo in stone clearance after 
ESWL117. Treatment with the terpene combination is well tolerated. However, in another 
randomized trial of 100 patients published in 2009, while Rowatinex improved initial stone 
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passage there was no clinical difference at the trial end118. And in a 90 patients trial by Aldemir 
et al. in 2011 Rowatinex was inferior to tamsulosin in stone expulsion rates119. 
4.2.2.11 Calcium-channel blockers 
Nifedipine, an antihypertensive drug, has been the most studied of calcium-channel blockers. 
Similar to alpha-1 blockers it is used as part of medical expulsive therapy for selected ureteric 
stones, although it may be less effective114. In the recent SUSPEND trial it was to be no more 
effective than placebo109. Nifedipine reduces contractility of the distal ureter similarly to alpha-
adrenergic blockers allowing improved stone passage120. It is used off-label for medical 
expulsion therapy. Predictably, Nifedipine can cause dizziness and hypotension and can 
therefore precipitate or worsen underlying ischemic heart disease. Other side effects include 
peripheral edema, liver function test derangement and cholestasis or even allergic hepatitis121. 
Patients can experience flushing, headache, weakness, nausea, muscle cramps and tremor. 
4.3 Conclusion 
There are many different pharmacologic treatments available for the treatment of urinary tract 
stones.  However, each has unique benefits and harms and tailored treatment strategies are 
necessary in order to appropriately utilize the available options.  As we learn more about the 
mechanisms and etiology of stone formation itself we are hopeful that novel agents continue to 
be developed to optimally treat patients afflicted with this disease  
 4.4 Expert opinion  
This paper provides an up-to-date summary of the literature on medical management of renal 
stone disease. Key findings include strong evidence for thiazide and potassium citrate use in 
calcium stones and widespread and effective use of NSAID medications for management of 
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renal colic pain. The subject of MET (medical expulsive therapy) with alpha1 blockers or 
calcium-channel blockers remains controversial owing to a recent randomized controlled trial of 
over 1100 patients with no evidence of improved stone passage in the treatment vs. placebo 
groups109.  Despite this finding, some are critical of the fact that the study was not specifically 
powered to detect a difference in distal ureteral stones where the effect of MET is felt to be the 
strongest.  Furthermore, these findings go against the results of previously published meta-
analyses113 and are sure to generate discussion, in particular relating to stone management 
guidelines.  Another area requiring further study is the complex metabolism of citrate, acting as a 
stone inhibitor while simultaneously raising urinary pH with increased risk of calcium phosphate 
stone formation. Further studies are required to evaluate this process in more detail.  With regard 
to stone prevention, the only recent new drug used for stone prevention is febuxostat. A trial in 
201348 has confirmed significantly lowered 24-hour uric acid excretion. However, as yet we have 
no data on calcium or uric acid stone prevention with this drug. The majority of trials on stone 
prevention are more than 25 years old.  In the meantime our understanding of stone disease has 
evolved significantly and there may well be multiple new avenues for intervention. For example, 
a pharmaceutical company is currently trialing a new oxalate-reducing drug122 that may be of 
benefit in patients with hyperoxaluria. Perhaps, one day in the future we will have a full 
armamentarium of effective medical options to prevent various stone types so that surgical 
treatment is only of historical interest. 
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5. Article highlights 
 
• Renal stones are common and cause significant morbidity 
• Thiazide-type diuretics reduce urinary calcium excretion and calcium stone formation 
• Allopurinol and newer febuxostat xanthine-oxidase inhibitors reduce uric acid excretion 
• Various NSAID analgesics are the mainstay of symptomatic treatment of renal colic 
• Effectiveness of medical expulsion therapy with alpha-blockers or calcium channel 
blockers is currently being debated  
 
 
6. Appendix - Preventive pharmacological therapies – urinary alkalinizers123 
Potassium Citrate 5 mEq 
Potassium Citrate 10 mEq 
Potassium Citrate 15 mEq 
Potassium Citrate 
Uro Cit K 5 
Uro Cit K 10 
Cytra-3 
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Cytra-K 
Cytra-LC 
Effer-K 
K-Citra 
Klor-con/EF 
Klor-vess 
Polycitra-K 
Polycitra-LC 
Resol 
Taron 
Sorbutuss NR 
Tricitrates Oral Solution USP 36,Tri-K 
Twin K 
Sodium Potassium Citrate 
Potassium Magnesium Citrate 
Calcium Citrate 
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